Zetia vs Lisinopril: Side-Effect Profile Head-to-Head

Why These Two Drugs Get Compared

Ezetimibe and lisinopril sit in different pharmacological classes, yet both appear on the same cardiometabolic prescribing lists for patients managing heart disease risk. A patient discharged after an acute coronary syndrome event may be placed on both simultaneously. The comparison matters because side-effect stacking can drive non-adherence, and understanding which drug causes which symptom helps clinicians adjust regimens without abandoning proven therapies.

No randomized controlled trial has ever directly compared ezetimibe with lisinopril. The evidence base for each drug's safety profile comes from separate landmark trials: IMPROVE-IT (N=18,144) for ezetimibe, published in the New England Journal of Medicine in 2015, and ALLHAT (N=33,357) for lisinopril, published in JAMA in 2002 [1][2]. All side-effect comparisons here are cross-trial observations, not direct head-to-head data.

Mechanism of Action and Why Side Effects Differ

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestinal brush border. That mechanism is local. The drug circulates enterohepatic but avoids major systemic enzyme pathways, which explains its generally mild adverse-event profile. The FDA-approved prescribing label lists GI complaints, fatigue, and myalgia (especially when combined with statins) as the primary tolerability concerns [3].

Lisinopril inhibits angiotensin-converting enzyme systemically, blocking the conversion of angiotensin I to angiotensin II. This lowers blood pressure and reduces cardiac afterload. The same enzyme also degrades bradykinin. Accumulated bradykinin in the airways drives the persistent dry cough that is the hallmark complaint of all ACE inhibitors. The 2017 ACC/AHA Hypertension Guideline acknowledges cough as a class-wide issue and notes a switch to an ARB resolves it in most cases [4].

The pharmacological distinction is simple. Ezetimibe works in the gut. Lisinopril works systemically. That difference in distribution predicts their distinct side-effect signatures.

Ezetimibe (Zetia): Detailed Side-Effect Profile

The adverse-event data for ezetimibe come primarily from IMPROVE-IT and the manufacturer's pooled Phase III safety database. In IMPROVE-IT, ezetimibe 10 mg added to simvastatin 40 mg was compared against simvastatin 40 mg plus placebo over a median follow-up of 6 years [1].

Rates of myopathy (creatine kinase >10x ULN) were 0.2% in the ezetimibe/simvastatin arm versus 0.1% in the simvastatin-alone arm. Hepatitis or hepatic enzyme elevations (>3x ULN for ALT or AST) occurred in 2.5% of the combination group versus 2.3% of the monotherapy group. The difference was not statistically significant (P=0.43). Gallbladder-related events appeared in 3.1% versus 3.5%, respectively. Drug discontinuation due to adverse events occurred in 10.1% of the combination arm over 6 years [1].

Outside the statin combination, monotherapy side effects reported at rates exceeding placebo in pooled Phase III data include:

• Diarrhea: 3.7% vs 3.0% placebo
• Upper respiratory tract infection: 4.3% vs 3.6% placebo
• Arthralgia: 3.0% vs 2.2% placebo
• Sinusitis: 2.8% vs 2.2% placebo
• Fatigue: 2.4% vs 1.5% placebo

Per the FDA label, post-marketing reports include rare cases of rhabdomyolysis (almost always with concurrent statin use), hypersensitivity reactions including anaphylaxis, and pancreatitis [3].

The 2019 ESC/EAS Dyslipidaemia Guidelines describe ezetimibe as "well-tolerated" and recommend it as first-line add-on therapy when statins alone do not achieve LDL-C targets. The guideline committee noted that "the safety profile of ezetimibe is well established with over two decades of post-marketing surveillance" [5].

Lisinopril: Detailed Side-Effect Profile

Lisinopril's safety data draw from ALLHAT, numerous smaller hypertension trials, and decades of prescribing experience. ALLHAT randomized 33,357 participants aged 55 and older with hypertension and at least one additional cardiovascular risk factor to chlorthalidone, amlodipine, or lisinopril [2].

The headline tolerability finding from ALLHAT: lisinopril carried a higher discontinuation rate than chlorthalidone. Over the 4.9-year mean follow-up, 1.3% more participants discontinued lisinopril versus the diuretic comparator, and blood pressure control was worse in the lisinopril arm (mean 2 mmHg higher systolic) [2].

The dry cough stands as the most recognizable ACE inhibitor side effect. Prevalence estimates range from 5% to 12% across studies, though some populations experience higher rates. A meta-analysis published in the Annals of Internal Medicine reported ACE inhibitor cough at 5 to 35% in unselected populations, with women and East Asian patients disproportionately affected [6]. The cough is nonproductive, persistent, and typically appears within the first few months of therapy.

Angioedema is the most dangerous ACE inhibitor side effect. The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) study found ACE inhibitor-associated angioedema in approximately 0.68% of treated patients, with Black patients carrying a 3-fold higher incidence compared with non-Black patients [7]. The reaction can involve the lips, tongue, glottis, or larynx and may be life-threatening. It can occur at any point during therapy, even after years of stable dosing.

Other reported side effects of lisinopril include:

• Hyperkalemia: risk increases with renal impairment, diabetes, or concurrent potassium-sparing diuretics
• Hypotension: particularly with first dose; more common in volume-depleted patients
• Dizziness: reported in 5 to 12% of users
• Headache: reported in 3 to 6%
• Elevated serum creatinine: typically mild and reversible; monitor renal function at baseline, 1 to 2 weeks, and periodically
• Taste disturbance (dysgeusia): uncommon but reported

The ACC/AHA guideline notes that ACE inhibitors are contraindicated in patients with a history of angioedema and in pregnancy (teratogenic in second and third trimesters) [4].

Discontinuation Rates: A Proxy for Real-World Tolerability

Trial discontinuation rates provide the closest available proxy for comparing tolerability across drugs that were never tested together.

IMPROVE-IT recorded a 10.1% adverse-event-driven discontinuation rate in the ezetimibe/simvastatin arm over a median of 6 years [1]. Isolating ezetimibe's contribution is difficult because simvastatin was co-administered, but the rate was nearly identical to the simvastatin-only arm (9.9%). That near-equivalence suggests ezetimibe itself added minimal discontinuation burden.

In ALLHAT, overall discontinuation for any reason was approximately 22% in the lisinopril arm by the end of the trial [2]. The lisinopril group also showed higher rates of metabolic side effects (hypokalemia was less common than with chlorthalidone, but hyperkalemia was more frequent). The diuretic and calcium channel blocker arms both retained more patients on assigned therapy.

A 2018 real-world adherence analysis in the Journal of the American Heart Association found that ACE inhibitor adherence at 12 months averaged around 60 to 65%, with cough cited as the leading tolerability-related cause of switching [8]. Statin/ezetimibe combination adherence in similar observational data tracked at roughly 55 to 60%, though statin-related complaints (myalgia, in particular) rather than ezetimibe-specific issues drove most switches.

Drug Interactions That Affect Safety

Ezetimibe has a relatively clean interaction profile. The main concern is cyclosporine, which increases ezetimibe exposure by approximately 3.4-fold according to the FDA prescribing information [3]. Fibrates may also increase gallstone risk when co-administered. No CYP450 interactions of clinical significance have been identified.

Lisinopril interactions carry higher clinical stakes. Potassium supplements, potassium-sparing diuretics (spironolactone, eplerenone, amiloride), and trimethoprim all increase hyperkalemia risk. NSAIDs blunt the antihypertensive effect and worsen renal function in susceptible patients. Lithium levels rise when combined with ACE inhibitors, requiring closer monitoring. The FDA label for lisinopril carries specific warnings against dual renin-angiotensin blockade (combining ACE inhibitor with ARB or aliskiren) due to increased risks of hypotension, hyperkalemia, and renal impairment [9].

For patients on both drugs simultaneously, no known direct interaction between ezetimibe and lisinopril exists. They may be co-prescribed safely from a drug-interaction perspective.

Special Populations: Who Tolerates Which Drug Better

Older adults: Ezetimibe is generally well-tolerated in patients over 65. In IMPROVE-IT, the subgroup aged 75 and older showed no excess adverse events versus placebo [1]. Lisinopril requires more caution in older adults due to orthostatic hypotension and renal sensitivity. ALLHAT demonstrated worse blood pressure control with lisinopril in Black participants and older subgroups compared with chlorthalidone [2].

Patients with renal impairment: Ezetimibe does not require dose adjustment in renal impairment. Lisinopril requires careful titration and monitoring of serum creatinine and potassium. A rise in creatinine of up to 30% above baseline is considered acceptable with ACE inhibitor initiation, per the KDIGO 2021 Blood Pressure Guideline, but larger increases warrant dose reduction or discontinuation [10].

Patients with hepatic impairment: Ezetimibe is contraindicated in moderate-to-severe hepatic impairment when combined with a statin, due to the statin component's hepatotoxicity risk. Ezetimibe monotherapy is not recommended in active liver disease. Lisinopril, by contrast, undergoes no hepatic metabolism. It is excreted unchanged by the kidneys, making it one of the few antihypertensives safe to use in patients with liver disease.

Pregnant patients: Both drugs are contraindicated. Lisinopril is teratogenic (Category D under the old FDA system). Ezetimibe lacks adequate human data and should not be used during pregnancy, especially in combination with a statin.

When Clinicians Choose One Over the Other

This framing needs correction. These drugs are not interchangeable alternatives. A clinician does not choose ezetimibe instead of lisinopril, because they treat different conditions. Ezetimibe lowers LDL cholesterol. Lisinopril lowers blood pressure and provides renal protection in diabetic nephropathy.

The real clinical question is whether both are tolerated in the same patient. If a patient reports a persistent dry cough, the clinician should first rule out other causes and then consider switching lisinopril to an ARB (such as losartan or valsartan). The 2017 ACC/AHA guideline lists ARBs as the recommended alternative when ACE inhibitor cough is intolerable [4]. If a patient on ezetimibe/statin combination reports muscle aches, reducing the statin dose or switching statins is the first step. Stopping ezetimibe alone rarely resolves myalgia since the statin is almost always the culprit.

The Side-Effect Summary: Side by Side

Ezetimibe wins on:

• Lower discontinuation rate in its landmark trial
• No cough
• No angioedema risk
• Minimal drug interaction burden
• No blood pressure-related side effects

Lisinopril wins on:

• No hepatic enzyme concerns
• No gallbladder signal
• Safe in liver disease (no hepatic metabolism)
• Decades-long safety record with well-characterized risk management

The 2019 ESC/EAS Guidelines state that ezetimibe "adds very little to the risk of adverse events when added to statin therapy" [5]. The ACC/AHA Hypertension Guideline characterizes ACE inhibitors as "well-tolerated in most patients," with cough and angioedema as the primary limitations [4].

Patients who take both drugs should report any new cough (likely lisinopril), muscle pain (likely the statin, not ezetimibe), or swelling of the face or throat (lisinopril, requires emergency evaluation) to their prescribing clinician within 24 hours.